Alexion Pharmaceuticals (NASDAQ:ALXN) : 15 investment research analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN) have an average price target of $193.47 for the near short term. The highest target price given by the Brokerage Firm to the stock is $221 and the lowest target is $145 for the short term. Analysts expect the variance to be within $24.47 of the average price.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Brokerage Firm, Morgan Stanley, maintains their rating on the shares of Alexion Pharmaceuticals (NASDAQ:ALXN). Morgan Stanley has a Overweight rating on the shares. As per the latest research report, the brokerage house lowers the price target to $189 per share from a prior target of $203. The rating by the firm was issued on June 7, 2016.
Alexion Pharmaceuticals (NASDAQ:ALXN): stock turned positive on Thursday. Though the stock opened at $123.08, the bulls momentum made the stock top out at $123.71 level for the day. The stock recorded a low of $121.43 and closed the trading day at $123.57, in the green by 1.78%. The total traded volume for the day was 1,922,846. The stock had closed at $121.41 in the previous days trading.
The company shares have dropped -34.69% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $208.88 and the one year low was seen on Jun 22, 2016. The 50-Day Moving Average price is $140.40 and the 200 Day Moving Average price is recorded at $151.19. On the companys insider trading activities, Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, unloaded 918 shares at an average price of $135.72 on June 13, 2016. The total amount of the transaction was worth $124,591, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.